Peer-review policy
Clinical and Translational Allergy operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
The Editor-in-Chief or nominated Handling Editor will invite appropriate reviewers, who will who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
An official journal of EAACI
Follow
Annual Journal Metrics
-
Speed
41 days to first decision for reviewed manuscripts only
30 days to first decision for all manuscripts
121 days from submission to acceptance
32 days from acceptance to publicationCitation Impact
3.539 - 2-year Impact Factor
1.188 - Source Normalized Impact per Paper (SNIP)
1.425 - SCImago Journal Rank (SJR)Usage
444,454 Downloads
1,577 Altmetric Mentions